Gavin MacBeath Selected Research

seribantumab

12/2021	Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors.
1/2017	A phase 1 study combining the HER3 antibody seribantumab (MM-121) and cetuximab with and without irinotecan.
1/2017	Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121).
12/2016	Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer.
11/2015	Seribantumab, an Anti-ERBB3 Antibody, Delays the Onset of Resistance and Restores Sensitivity to Letrozole in an Estrogen Receptor-Positive Breast Cancer Model.
7/2014	Combination of anti-HER3 antibody MM-121/SAR256212 and cetuximab inhibits tumor growth in preclinical models of head and neck squamous cell carcinoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Gavin MacBeath Research Topics

Disease

17	Neoplasms (Cancer) 08/2022 - 01/2006
3	Breast Neoplasms (Breast Cancer) 01/2017 - 11/2014
2	Ovarian Neoplasms (Ovarian Cancer) 01/2017 - 12/2016
2	Carcinogenesis 01/2017 - 05/2013
2	Colorectal Neoplasms (Colorectal Cancer) 01/2017 - 04/2010
2	Squamous Cell Carcinoma of Head and Neck 10/2015 - 07/2014
1	Residual Neoplasm 01/2021
1	Melanoma (Melanoma, Malignant) 01/2021
1	COVID-19 11/2020
1	Common Cold 11/2020
1	Neoplasm Metastasis (Metastasis) 01/2019
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2017
1	Diarrhea 01/2017
1	Exanthema (Rash) 01/2017
1	Lung Neoplasms (Lung Cancer) 01/2017
1	Paronychia 01/2017
1	Stomatitis 01/2017
1	Cholangiocarcinoma 01/2017
1	Disease Progression 01/2017
1	Head and Neck Neoplasms (Head and Neck Cancer) 10/2015
1	Infections 10/2014
1	Stomach Neoplasms (Stomach Cancer) 11/2013
1	Malaria 03/2013
1	Triple Negative Breast Neoplasms 05/2012

Drug/Important Bio-Agent (IBA)

6	seribantumabIBA 12/2021 - 07/2014
6	Proteins (Proteins, Gene)FDA Link 11/2020 - 01/2006
4	LigandsIBA 01/2019 - 07/2013
3	AntigensIBA 08/2022 - 01/2019
3	Monoclonal AntibodiesIBA 12/2021 - 07/2014
3	ErbB Receptors (EGF Receptor)IBA 12/2021 - 01/2011
3	Messenger RNA (mRNA)IBA 01/2017 - 10/2015
3	Biomarkers (Surrogate Marker)IBA 12/2016 - 11/2013
3	Phosphotransferases (Kinase)IBA 05/2013 - 01/2006
3	tyrosine receptor (receptor, tyrosine)IBA 05/2013 - 01/2006
2	Peptides (Polypeptides)IBA 01/2021 - 11/2020
2	EpitopesIBA 01/2021 - 11/2020
2	Cetuximab (Erbitux)FDA Link 01/2017 - 07/2014
2	histidine-rich proteinsIBA 01/2017 - 12/2016
2	PlatinumIBA 01/2017 - 12/2016
2	Neuregulin-1 (Neuregulin 1)IBA 11/2015 - 10/2015
2	human ERBB2 proteinIBA 10/2015 - 11/2013
1	AutoantigensIBA 08/2022
1	HLA Antigens (Human Leukocyte Antigens)IBA 01/2021
1	Immune Checkpoint InhibitorsIBA 01/2021
1	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 01/2019
1	Proto-Oncogene Proteins c-metIBA 01/2019
1	Epithelial Cell Adhesion MoleculeIBA 01/2019
1	Hormones (Hormone)IBA 01/2017
1	Irinotecan (Camptosar)FDA LinkGeneric 01/2017
1	Pharmaceutical PreparationsIBA 01/2017
1	Phosphatidylinositols (Phosphatidylinositol)IBA 01/2017
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2017
1	Paclitaxel (Taxol)FDA LinkGeneric 12/2016
1	Aromatase InhibitorsIBA 11/2015
1	Letrozole (Femara)FDA LinkGeneric 11/2015
1	Estrogen ReceptorsIBA 11/2015
1	Phosphatidylinositol 3-Kinases (PI 3 Kinase)IBA 09/2015
1	Protein Isoforms (Isoforms)IBA 10/2014
1	PhosphotyrosineIBA 05/2013
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 05/2013
1	Tyrosine (L-Tyrosine)FDA Link 05/2013
1	DNA (Deoxyribonucleic Acid)IBA 05/2012
1	Transcription Factors (Transcription Factor)IBA 04/2010

Therapy/Procedure

8	Therapeutics 08/2022 - 07/2014
1	Immunotherapy 08/2022
1	Drug Therapy (Chemotherapy) 05/2012